0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Morbidity and Toxic Effects Associated With Ganciclovir or Foscarnet Therapy in a Randomized Cytomegalovirus Retinitis Trial

Richard A. Lewis, MD, MS; Pamela Clogston, COT; Victor Fainstein, MD; Ronald Gross, MD; Tobias Samo, MD; Colette Tuttle, RN; Douglas A. Jabs, MD; Linda Apuzzo; John Bartlett, MD; Laura Coleson, RN, MPH; J. P. Dunn, MD; Lois Eldred, PA-C; Judith Feinberg, MD; Thomas Flynn, MD; Rosemary King, PA-C; Jo Leslie, PA-C; Bruce Barron, MD; Deborah Greenspan, RN; Cynthia Le-Count; Gholam Peyman, MD; Rudolph Franklin, MD; Murk-Hein Heinemann, MD; Bruce Polsky, MD; Kathleen Squires, MD; Susanne Wise-Campbell, RN; Alan H. Friedman, MD; Tony W. Cheung, MD; Norma Justin, MS; Steven Teich, MD; Henry Sacks, MD, PhD; Colette Severin, MS; Dorothy N. Friedberg, MD, PhD; Adrienne Addessi, MA, RN; Douglas Dieterich, MD; Kevin Frost; David Weinberg, MD; Lee Jampol, MD; Robert Murphy, MD; Kathleen Naughton, RN; Dale Henderly, MD; Gary N. Holland, MD; Suzette Chafey, RN, NP; Holly Fall, RN, MN, NP; W. David Hardy, MD; Chris Kimbrell, RN; Lesley J. MacArthur, MA; William R. Freeman, MD; Linda Meixnert, RN; Timothy J. Peterson, MD; Jose I. Quiceno, MD; Leland Rickman, MD; Mary Ann Simanello, RN; Stephen Spector, MD; James O'Donnell, MD; Jacqueline Hoffman; Alexander Irvine, MD; Mark Jacobson, MD; James Larson, COT; Stuart Seiff, MD; Maxine Wanner; Janet Davis, MD; Elaine Chuang, MD; Millie Espinal; Paul Mendez, MD; Ruth Vandenbroucke; Sarah H. Cheeseman, MD; John Gittinger, MD; Richard Haubrich, MD; Harry Kachadoorian, CRA; Karen Tolson; Joan M. Kline; Amy C. Klemm; Maria Stevens; Rene Webb; Jude Brown-Bellamy, MAS; Jan A. Markowitz, PhD; Curtis L. Meinert, PhD; Karen L. Binder; Ronald Brookmeyer, PhD; Vivian E. Brown; Betty J. Collison; John Dodge; Michele Donithan, MHS; Nancy Fink, MPH; Charlotte Gerczak, MLA; Janet T. Holbrook, MS, MPH; Milana R. Isaacson; Camara P. Jones, MD, MPH; Charlene R. Levine; Yuan-I Min, MPH; J. L. Meinert; Rosetta M. Owens; Deborah J. Nowakowski; A. Saah; Gordon R. Sandford, MD; Stephen Singer; Michael Smith; Alice L. Sternberg, ScM; James Tonascia, PhD; Mark L. Van Natta, MHS; Matthew D. Davis, MD; Maria Agres-Segal; Jane Armstrong; Rosemary Brothers; Ginger Freitag; Larry Hubbard, MAT; Dolores Hurlburt; Linda Kastorff; Yvonne Magli; Kathleen Miner; Suzanne Thomas; Marilyn Vanderhoof-Young; Gary Stewart, MS, RPh; Robert Hughes; Lisa Welch, RPh, MAS; Richard Mowery, PhD; Susan Ellenberg, PhD; Joyce Korvick, MD; Tom Clark, CRA; Pamela S. Clogston; William Freeman, MD; Larry Hubbard, MA; Fred Sattler, MD; Colin Jordan, MD; John Mills, MD; Byron W. Brown Jr, PhD; Brian Conway, MD; James Grizzle, PhD; Robert Nussenblatt, MD; John Phair, MD; Harmon Smith, PhD
Arch Intern Med. 1995;155(1):65-74. doi:10.1001/archinte.1995.00430010071010.
Text Size: A A A
Published online

Background:  The Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial compared the use of either ganciclovir or foscarnet for the initial treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. We previously reported that patients treated with foscarnet lived longer but were more likely to have their treatment switched, the latter suggesting foscarnet may not have been as well tolerated as ganciclovir. This study compared the morbidity and toxic reactions reported during the trial.

Methods:  Two hundred thirty-four patients with the acquired immunodeficiency syndrome and previously untreated cytomegalovirus retinitis at 11 university centers were randomly assigned to receive intravenously either foscarnet (n=107) or ganciclovir (n=127). Medical histories, laboratory tests, and drug treatment histories during the first 6 months of treatment were analyzed.

Results:  Neutropenia was more common in patients assigned to ganciclovir than to foscarnet (34% vs 14%; P=.001). Patients assigned to foscarnet reported more infusion-related symptoms (58% vs 24%; P<.001) and, in male patients, more genitourinary symptoms (36% vs 16%; P>.001); they also experienced a trend toward more nephrotoxic effects (13% vs 6%; P=.082) and electrolyte abnormalities. The incidence of seizures was similar in both groups (foscarnet, 12%; ganciclovir, 9%; P=.511). Patients assigned to foscarnet were more likely to be switched to the alternative treatment (foscarnet to ganciclovir, 46%; ganciclovir to foscarnet, 11%; P<.001), and most of this excess was attributable to toxic reactions. In 88% of cases in which treatment was switched as a result of toxic reactions and in which follow-up data were available, the toxic reaction resolved after the switch. No permanent disability or death resulted from toxic reactions.

Conclusions:  Compared with ganciclovir, the use of foscarnet was more frequently limited by the occurrence of toxic reactions. However, these toxic reactions rarely had long-term sequelae. In light of the previously reported survival benefit seen in patients treated with foscarnet, these data support the use of foscarnet for the initial treatment of cytomegalovirus retinitis.(Arch Intern Med. 1995;155:65-74)

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 28

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();